Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 6Leukemia, Myelomonocytic, Chronic 3Neoplasms 2Advanced Solid Neoplasm 2Solid Tumors 1Renal Insufficiency 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma 1Lymphoma 1Lung Neoplasms 1Liver Diseases 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1

Interventions

tislelizumab 4talazoparib 4pembrolizumab 4Docetaxel 4Nivolumab 3PM 01183 2MLN 8237 2Itraconazole 2Fluorouracil 2Cisplatin 2Carboplatin 2zimberelimab 1utomilumab 1urelumab 1ulixertinib 1trifluridine tipiracil drug combination 1sitravatinib 1sapanisertib 1pexidartinib 1pevonedistat 1peposertib 1niraparib 1mogamulizumab 1lenvatinib 1ixabepilone 1eribulin 1durvalumab 1dalotuzumab 1avelumab 1ascrinvacumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Solid Tumors × pevonedistat × Clear all
NCT02122770 2019-01-07

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

Takeda

Phase 1 Completed
51 enrolled 30 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡